Dr Gunnel Halldén

Gunnel Halldén

Academic

Barts Cancer Institute
Queen Mary University of London
020 8888 3593

Research

oncolytic virus, prostate cancer, pancreatic cancer

Interests

virology, adenovirus, cell killing modes, novel therapeutics

Publications

solid heart iconPublications of specific relevance to Predictive in vitro Models

2023

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports, Springer Nature vol. 75 (3), 753-753.  
17-05-2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al.
Pharmacological Reports, Springer Nature vol. 75 (3), 570-584.  
03-04-2023

2021

Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy
Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM et al.
Acta Biomaterialia, Elsevier vol. 134, 593-604.  
26-07-2021

2019

Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer
Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G
Scientific Reports, Springer Science and Business Media Llc vol. 9 (1) 
06-09-2019
Improved replication and selectivity of oncolytic Ad Delta Delta and Ad-3 Delta-A20T promotes targeting to distant lesions in preclinical pancreatic cancer models
Hallden G
IAM 2020 2021. 
01-08-2019
ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY
Hallden G, Wang Y, Wong H-H, Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology, World Scientific Publishing 323-345.  
17-07-2019

2018

Advances in oncolytic adenovirus therapy for pancreatic cancer
Nattress CB, Halldén G
Cancer Letters, Elsevier vol. 434, 56-69.  
05-07-2018
Designer Oncolytic Adenovirus: Coming of Age
Baker AT, Aguirre-Hernández C, Halldén G, Parker AL
Cancers, Mdpi vol. 10 (6) 
14-06-2018
The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells
Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr) vol. 17 (2), 575-587.  
01-02-2018
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy
Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu Y-J, Halldén G
Oncogenesis, Springer Nature vol. 7 (1) 
24-01-2018

2017

Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad Delta Delta through Bcl-2-dependent attenuation of autophagy
Aguirre-Hernandez C, Maya-Pineda H, Millan JS, Man YKS, Lu YJ, Hallden G
ESGCT workshop Croatia. 
01-12-2017
The novel oncolytic adenoviral mutant Ad5-3 Delta-A20T retargeted to alpha v beta 6-integrins efficiently eliminates pancreatic cancer cells
Man YKS, Davies JA, Coughlan L, Pantelidou C, Marshall JF, Parker AL, Hallden G
IAM Mexico. 
01-12-2017
Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses
Hallden G
 
01-08-2017

2016

Oncolytic adenovirus-mediated therapy for prostate cancer
Sweeney K, Halldén G
Oncolytic Virotherapy, Taylor & Francis vol. 5, 45-57.  
01-07-2016
The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells.
Hernandez CA, Hallden G
ESGCT London. 
01-07-2016
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11
Pantelidou C, Cherubini G, Lemoine NR, Halldén G
Oncotarget, Impact Journals vol. 7 (13), 15703-15724.  
10-02-2016
Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage
Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H, Hallden G
International Journal of Molecular Medicine vol. 38, S58-S58.  
01-01-2016
The adenoviral AdΔΔ mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells.
Aguirre-Hernandez C, Millan JS, Hallden G
 
01-01-2016

2015

An oncolytic adenovirus (AdΔ19K) sensitizes pancreatic cancer cells to cytotoxic drugs by promoting DNA-damage and aberrant mitosis through inactivation of checkpoint mediators.
Pantelidou C, Hallden G
 
01-01-2015

2014

Abstract 713: Utilizing a potent and selective nonreplicating adenoviral mutant (Ad5-TV-CU), with gene expression controlled by androgen receptor-dependent activation domains in the TMPRSS2 gene, as a novel prodrug-converting enzyme therapy for prostate cancer
Mercer EJ, Imrali A, Sharpe K, Hallden G, Lu Y-J
 
01-10-2014
18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY
Hallden G, Wang Y, Wong H-H, Lemoine NR
In Advanced Textbook On Gene Transfer, Gene Therapy and Genetic Pharmacology, World Scientific Publishing 307-329.  
14-01-2014
Oncolysis is greatly enhanced by retargeting of replication-selective adenoviral mutants to avβ6-integrin expressing cancers and in combination with cytotoxic drugs
Man YKS, Coughlan L, Pantelidou C, Hallden G
 
01-01-2014
Adenoviruses deleted in the anti-apoptotic E1B19K-gene synergise with DNA-damaging drugs through attenuation of DNA-damage repair responses and checkpoint activation in pancreatic cancer cells
Pantelidou C, Lemoine N, Hallden G
 
01-01-2014

2013

Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells.
Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G et al.
Endocr Relat Cancer vol. 20 (5), 633-647.  
01-10-2013

2012

Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.
Halldén G, Portella G
Expert Opin Ther Targets vol. 16 (10), 945-958.  
01-10-2012
Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.
Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR et al.
Hum Gene Ther vol. 23 (9), 1003-1015.  
01-09-2012
Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo.
Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F et al.
Hum Gene Ther vol. 23 (6), 623-634.  
01-06-2012
Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells
Sweeney KG, Cheong SC, Lemoine NR, Hallden G
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2712-2712.  
15-04-2012
Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells
Maya-Pineda HR, Miranda-Rota E, Lemoine NR, Halldén G
Cancer Research, American Association For Cancer Research (Aacr) vol. 72 (8_Supplement), 2713-2713.  
15-04-2012
Adenoviral gene expression and replication in human tumor explant models.
Halldén G
Methods Mol Biol vol. 797, 65-78.  
01-01-2012
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G
Plos One vol. 7 (10) 
01-01-2012

2011

The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.
Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G
Gene Ther vol. 18 (12), 1157-1165.  
01-12-2011
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G
Cancer Gene Ther vol. 18 (10), 734-743.  
01-10-2011
Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene
Pantelidou C, Cherubini G, Lemoine NR, Hallden G
Human Gene Therapy vol. 22 (10), A119-A120.  
01-01-2011
A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells
Sweeney K, Cheong SC, Lemoine N, Hallden G
Human Gene Therapy vol. 22 (10), A122-A122.  
01-01-2011
Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells
Maya-Pineda H, Miranda E, Lemoine N, Hallden G
Human Gene Therapy vol. 22 (10), A104-A104.  
01-01-2011

2010

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.
Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G, McNeish IA
Oncogene vol. 29 (45), 6051-6063.  
11-11-2010
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G
Hum Gene Ther vol. 21 (10), 1311-1325.  
01-10-2010
A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells
Sweeney K, Cheong SC, Lemoine N, Hallden G
 
01-10-2010
Development of an oncolytic adenovirus expressing the prodrug-converting enzyme CD/UPRT (Ad Delta Delta CU)
Ekblad M, Oberg D, Lemoine N, Hallden G
 
01-10-2010
Investigating a new potent and selective oncolytic adenovirus (Ad Delta Delta) in combination with chemotherapy
Cherubini G, Kalllin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N, Hallden G
 
01-10-2010
Adenovirus-based therapy for prostate cancer.
Ekblad M, Halldén G
Curr Opin Mol Ther vol. 12 (4), 421-431.  
01-08-2010
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Halldén G
Clin Cancer Res vol. 16 (2), 541-553.  
15-01-2010

2009

P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion.
Lee M, Choi S, Halldén G, Yo SJ, Schichnes D, Aponte GW
Am J Physiol Gastrointest Liver Physiol vol. 297 (4), G641-G654.  
01-10-2009
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics
Hallden G
J Buon vol. 14, S61-S67.  
01-09-2009
Critical Role for p21 and p27 in Efficacy of Oncolytic Adenovirus dl922-947 in Ovarian Cancer
Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA
 
01-05-2009
Prostate Cancer Targeting by Replication-Selective Adenoviral Mutants: Combination Treatments with Phytochemical Drugs
Adam V, Oberg D, Lemoine N, Hallden G
 
01-05-2009
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G
Clin Cancer Res vol. 15 (5), 1730-1740.  
01-03-2009

2008

Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947
Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G, Portella G
Clin Cancer Res vol. 14 (20), 6505-6514.  
15-10-2008
Inhibition of late-stage prostate cancer using adenoviral mutants: Expression of an androgen receptor co-repressor and AR-siRNA
Cheong SC, Oberg D, Nick L, Hallden G
 
01-10-2008
Prostate cancer targeting by replication-selective adenoviral mutants: combination treatments with phytochemical drugs
Adam V, Lemoine N, Hallden G
 
01-10-2008
Host cell factors in ovarian cancer influencing efficacy of oncolytic adenovirus dl922-947
Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA
 
01-10-2008
Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V et al.
Hum Gene Ther vol. 19 (9), 873-886.  
01-09-2008
Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus.
Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V et al.
Hum Gene Ther 
27-06-2008
Prostate cancer targeting by replication-selective adenoviral mutants: Combination treatments with phytochemical drugs
Adam VS, Lemoine N, Hallden G
 
01-04-2008
E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.

Cancer Gene Ther vol. 15 (1), 40-50.  
01-01-2008

2007

Inhibition of androgen receptor signaling pathways in prostate cancer cells by adenoviral vectors expressing Hey1
Cheong SC, Lemoine N, Hallden G
 
01-10-2007
Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses
Gaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M
Cancer Res vol. 67 (15), 7284-7294.  
01-08-2007
Synergistic enhancement of prostate cancer cell death by combination therapy of adenovirus and chemotherapy
Radhakrishnan S, Hallden G, Chinegwundoh F, Lemoine N
 
01-06-2007
GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells
Choi S, Lee M, Shiu AL, Yo SJ, Hallden G, Aponte GW
Am J Physiol-Gastr L vol. 292 (5), G1366-G1375.  
01-05-2007
Lysis of dysplastic but not normal organotypical oral epithelium with conditionally replicating adenoviruses
Gaballah K, Partridge M, Hills A, Curiel D, Hallden G, Harrison P
 
01-05-2007
Synergistic enhancement of cell death by combination therapy with adenovirus and chemotherapy
Radhakrishnan S, Hallden GK, Chinegwundoh F, Lemoine N
 
01-04-2007

2006

Oncolytic virotherapy for nasopharyngeal cancer
Bapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G, Lemoine N
Clinical Otolaryngology, Wiley vol. 31 (6), 582-583.  
01-12-2006
Synergistic interactions between adenovirus and chemotherapy in pancreatic cancer cell lines: Effects of chemotherapy on expression of coxsackie-adenovirus receptor (CAR) and infectability by adenovirus
Bhattacharyya M, Hallden G, Francis J, Lemoine NR
 
01-01-2006

2005

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Gene Ther vol. 12 (17), 1333-1346.  
01-09-2005
Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.

Cancer Res vol. 65 (4), 1523-1531.  
15-02-2005
Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity.
Lee M, Hadi M, Halldén G, Aponte GW
J Biol Chem vol. 280 (1), 125-136.  
07-01-2005
A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Clin Cancer Res vol. 11 (1), 351-360.  
01-01-2005

2004

Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro.
Hu JC, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes C
 
15-07-2004
Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

Int J Oncol vol. 25 (1), 173-178.  
01-07-2004
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.

Mol Ther vol. 9 (6), 786-803.  
01-06-2004
Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture
Hallden GK, Meng JH, Hill R, Wang YH, Francis J, Lemoine NN, Kirn DH
 
01-05-2004
VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours
Wang YH, Xue SA, Hallden G, Francis J, Griffin BE, Lemoine NR
 
01-05-2004
Combination of a second generation genetically modified herpes simplex virus 1 (HSV 1) with paclitaxel in the treatment of breast cancer in vitro
Hu J, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes R
 
01-05-2004
Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity
Liu TC, Wang YH, Hallden G, Francis J, Brooks G, Lemoine N, Kirn D
 
01-05-2004
The gene expression and function of adenoviral E3-genes in murine tumour cell lines
Hill RJ, Hallden GK, Wang YH, Francis J, Simpson C, Kirn DH, Lemoine NR
 
01-05-2004
Replication-selective oncolytic adenoviruses.
Halldén G, Thorne SH, Yang J, Kirn DH
Methods Mol Med vol. 90, 71-90.  
01-01-2004

2003

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.

Nat Biotechnol vol. 21 (11), 1328-1335.  
01-11-2003
Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy.

Mol Ther vol. 8 (3), 412-424.  
01-09-2003
In vitro screening of murine carcinoma cell lines for testing of replication-competent oncolytic adenoviruses
Hill RJ, Hallden GK, Lemoine NR, Kirn DH
 
01-05-2003
Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor
Liu TC, Wang YH, Hallden G, Anand A, Lemoine NR, Kirn DH
 
01-05-2003
Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity
Liu TC, Hallden G, Anand A, Wang YH, Lemoine N, Kirn D
 
01-01-2003

2002

The emerging fields of suicide gene therapy and virotherapy.
Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ
Trends Mol Med vol. 8 (4 Suppl), S68-S73.  
01-01-2002

1994

Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells
Hallden G, Holehouse EL, Dong X, Aponte GW
American Journal of Physiology, American Physiological Society vol. 267 (4), g730-g743.  
01-10-1994

1989

Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells
Mulvihill SJ, Hallden G, Debas HT
Journal of Surgical Research, Elsevier vol. 46 (4), 327-329.  
01-04-1989
Purification of the pancreatic cholecystokinin receptor
Szecowka J, Hallden G, Goldfine ID, Williams JA
Peptides, Elsevier vol. 24 (3), 215-224.  
01-03-1989

Grants

solid heart iconGrants of specific relevance to Predictive in vitro Models
bullet iconIdentification of drugs that promote activation of the host anticancer immune-responses through enhancement of virus-mediated cell lysis
Gunnel Halldén
£199,906 PCRF Pancreatic Cancer Research Fund
01-12-2018 - 15-12-2022